findmyKOL

Marc Gautier, MD

Basic profile

Dartmouth–Hitchcock Medical Center

ORCIDNone on fileNPI
RegionLebanon, NH · NortheastSpecialtyHematology / OncologyFocusOncology
Last active 2022findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Marc Gautier is an Oncology physician affiliated with Dartmouth–Hitchcock Medical Center. OpenAlex indexes 18 publications with 325 citations (h-index 6); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
18publications

Distinct works indexed by OpenAlex.

325citations

Total citations across indexed works.

6h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1 Medical Center Dr
Section Of Hematology/ioncology
Lebanon, NH 037561000

Telephone

603-650-5529

Registry record last updated 13 Jul 2011.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    74.2%
    Thalidomide Analog25.1%
    Revlimid54%Pomalyst26%Lenalidomide19%
    Part D<11 patients
    Kinase inhibitor17%
    Jakafi26%Imbruvica23%Ibrance14%Tepmetko13%Imatinib Mesylate13%Calquence12%
    Part D<11 patients

    + 5 more classes in this area

  • Dermatology

    12.9%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.9%
    Acyclovir100%
    Part D15 patients
  • Metabolism & gastrointestinal

    4.7%
    Potassium supplement2.3%
    Potassium Chloride100%
    Part D<11 patients
    Corticosteroid2.3%
    Prednisone100%
    Part D<11 patients
Where care is delivered (Part B)4.9% facility · 95.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”